Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?

RAAS, a major pharmacological target in cardiovascular medicine, is inhibited by pharmacological classes including angiotensin converting enzyme (ACE) inhibitors (ACEIs), angiotensin-II type 1 blockers (ARBs) and aldosterone receptors antagonists, in addition to the recently introduced direct renin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hypertension research 2017-11, Vol.40 (11), p.903-909
Hauptverfasser:	Nehme, Ali, Zibara, Kazem
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiotensin Receptor Antagonists - administration & dosage Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - administration & dosage Angiotensin-Converting Enzyme Inhibitors - therapeutic use Antihypertensive Agents - administration & dosage Antihypertensive Agents - therapeutic use Biology Blood pressure Cardiovascular Diseases - drug therapy Cytochrome Dehydrogenases Diabetes Disease Efficiency Endocrine system Enzymes Heart attacks Heart failure Humans Hypertension Laboratories Mineralocorticoid Receptor Antagonists - administration & dosage Mineralocorticoid Receptor Antagonists - therapeutic use Morbidity Mortality Plasma Polypeptides Renin-Angiotensin System - drug effects Stem cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!